Development of a quantitative RT-PCR method to study 5α-reductase mRNA isozymes in rat prostate in different androgen status

Prostate

Volumn 56, Issue 1, 2003, Pages 74-79

  Torres, Jesus M ^a   Ruiz, Estrella ^a   Ortega, Esperanza ^a,b  

^a UNIVERSITY OF GRANADA   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

Author keywords

5 reductase isozymes; MRNA levels; Prostatic diseases; Testosterone and dihydrotestosterone

Indexed keywords

ANDROGEN; ISOENZYME; MESSENGER RNA; OXIDOREDUCTASE; STEROID 5ALPHA REDUCTASE;

ANDROGEN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY ELECTROPHORESIS; CARCINOGENESIS; CONTROLLED STUDY; ENZYME INHIBITION; HORMONE SYNTHESIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE HYPERTROPHY; QUANTITATIVE ANALYSIS; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA TRANSCRIPTION;

ANIMALS; DIHYDROTESTOSTERONE; ISOENZYMES; MALE; ORCHIECTOMY; ORGAN SIZE; PROSTATE; PROSTATIC DISEASES; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; TESTOSTERONE; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 0037904913     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10221     Document Type: Article

References (30)

1. Novelli G, Margiotti K, Sangiulo F, Reichardt JK. Pharmacogenetic of human androgens and prostate disease. Pharmacogenomics 2001;2(1):65-72.
2. Steers WD. 5alpha reductase activity in the prostate. Urology 2001;58:17-24.
3. Rusell DW, Wilson JD. Steroid 5alpha reductase: Two genes/two enzymes. Annu Rev Biochem 1994;63:25-61.
4. Andersson S, Russel DW. Structural and biochemical properties of cloned expressed human and rat steroid 5α-Reductase. Proc Natl Acad Sci USA 1990;87:3640-3644.
5. Thigpen AE, Silver RI, Guileyardo JM, Casey ML, McConnell JD, Rusell DW. Tissue distribution and ontogeny of steroid 5αreductase isozyme expression. J Clin Invest 1993;92:903-910.
6. Jaffe JM, Malkowicz SB, Walker AH, MacBride S, Peschel R, Tomaszewski J, Van Arsdalen K, Wein AJ, Rebbeck TR. Association of SRD5A2 genotype and pathological characterization of prostate tumors. Cancer Res 2000;60(6):1626-1630.
7. Latil AG, Azzouri R, Cancel GS, Guillaume EC, Cochan-Priollet B, Berthon PL, Cussenot O. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathway. Cancer 2001;92:1130-1137.
8. Shibata A, Stamey TA, McNeal JE, Cheng I, Peehl DM. Genetic polymorphism in the androgen receptor and type II 5 alphareductase genes in prostate enlargement. J Urol 2001;166:1560-1564.
9. Iehle C, Radvanyi F, Gil Diez de Medina S, Ouafik LH, Gerard H, Chopin D, Raynaud JP, Martin PM. Differences in steroid 5αreductase isoenzymes expression between normal and pathological human prostate tissue. J Steroid Biochem Mol Biol 1999;68:189-195.
10. George FW, Russel DW, Wilson JD. Feed-forward control of prostate growth: Dihydrotestosterone induces expression of its own biosynthetic enzyme, steroid 5 alpha-reductase. Proc Natl Acad Sci USA 1991;88:8044-8047.
11. Torres JM, Gomez-Capilla JA, Ortega E. Quantitative RT-PCR assay for mRNA levels of steroid 5-alpha-Reductase isozymes. Anal Biochem 2002;307:177-180.
12. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
13. Wong H, Anderson WD, Cheng T, Riabowol KT. Monitoring mRNA expression by polymerase chain reaction: The "primerdropping" method. Anal Biochem 1994;223:251-258.
14. Mahendroo MS, Cala KM, Hess DV, Rusell DW. Unexpected virilization in male mice lacking steroid 5α-reductase enzymes. Endocrinology 2001;142:4652-4662.
15. Smith CM, Ballard SA, Worman N, Buettner R, Masters JRW. 5αReductase expression by prostate cancer cell lines and benign prostatic hyperplasia in vitro. J Clin Endocrinol Metab 1996;81:1361-1366.
16. Berthaut I, Mestayer C, Portois MC, Cussenot O, Mowszowicz I. Pharmacological and molecular evidence for the expression of the two steroid 5 alpha-reductase isozymes in normal and hyperplastic human prostatic cells in culture. Prostate 1997;32:155-163.
17. Orly J, Rei Z, Greenberg NM, Richards JS. Tyrosine kinase inhibitor AG18 arrests follicle-stimulating hormone-induced granulosa cell differentiation: Use of reverse transcriptasepolymerase chain reaction assay for multiple messenger ribonucleic acids. Endocrinology 1994;134:2336-2346.
18. Gilliland G, Perrin S, Blanchard K, Bunn HF. Analysis of cytokine mRNA and DNA: Detection and quantitation by competitive polymerase chain reaction. Proc Natl Acad Sci USA 1990; 87:2725-2729.
19. Rappolee DA, Mark D, Banda MJ, Werb Z. Wound macrophages express TGF-alpha and other growth factors in vivo: Analysis by mRNA phenotyping. Science 1988;241:708-712.
20. Singer-Sam J, Robinson MO, Bellve AR, Simon MI, Riggs AD. Measurement by quantitative PCR of changes in HPRT, PGK-1, PGK-2, APRT, MTase, and Zfy gene transcripts during mouse spermatogenesis. Nucleic Acids Res 1990;18:1255-1259.
21. Meinhardt H. Models of biological pattern formation. New York: Academic; 1982.
22. Brawley OW, Barnes S, Parnes H. The future of prostate cancer prevention. Ann NY Acad Sci 2001;952:145-152.
23. Huynh H, Alpert L, Alaoui-Jamali MA, Ng CY, Chan TW. Coadministration of finasteride and the pure antioestrogen ICI 182, 780 act sinergistically in modulating the IGF system in rat prostate. J Endocrinol 2001;17:109-118.
24. Boyle P, Robertson C, Lowe F, Roehrborn C. Meta-analysis of clinical trials of Permixon in the treatment of symptomatic benign prostatic hyperplasia. Urology 2000;55:533-539.
25. Avila DM, Fuqua SA, George FW, McPhaul MJ. Identification of genes expresed in the rat prostate that are modulated diferently by castration and finasteride treatment. J Endocrinol 1998;159:403-411.
26. Kaplan SA. 5α-Reductase inhibitors, what role should they play? Urology 2001;58:65-70.
27. Bayne CW, Donelly F, Ross M, Habib FK. Serenoa repens (Permixon) a 5α-reductase types I and type II inhibitor new evidence in a coculture model of BPH. Prostate 1999;40:232-241.
28. Bayne CW, Ross M, Donnelly F, Habib FK. The selectivity and specificity of the actions of the lipo-sterolic extract of Serenoa repens (Permixon) on the prostate. J Urol 2000;164:876-881.
29. Di Silverio F, Monti S, Sciarra A, Varasano PA, Martini C, Lanzara S, D'Eramo G, Di Nicola S, Toscano V. Effects of long term treatment with Serenoa repens (Permixon) on the concentration and regional distribution of androgens and epidermal growth factor in BPH. Prostate 1998;37:77-83.
30. Thompson IM Jr., Kouril M, Klein EA, Coltman CA, Ryan A, Goodman P. The prostate cancer prevention trial: Current status and lessons learned. Urology 2001;57:230-234.